trial

Open-label Study of Curcumin C-3 Complex in Schizophrenia

NCTId NCT01875822
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 17 (actual)
Sponsored by Woodbury, Michel, M.D.
Primary completion 2011-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2009-06
Primary completion
2011-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Super-Curcumin

Sponsors

Woodbury, Michel, M.D.Lead Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sCollaborator

Investigators

1
Michel Woodbury Farina, MD ABPNStudy Director

Sites

1 total
San Juan, Puerto Rico

Linked catalysts

1
Open-label Study of Curcumin C-3 Complex in Schizophrenia — primary completion2011-10

Facts & assertions

4 sourced
Enrollment
17
Phase
PHASE1,PHASE2
Primary Completion Date
2011-10
Status
COMPLETED
relationships
The graph out of here
drug
Super-Curcumin
drug
lead_sponsor
Woodbury, Michel, M.D.
company
collaborator
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
company
indication
Schizoaffective Disorder
indication
Depression
indication
Psychotic Disorders
indication
investigator
Michel Woodbury Farina, MD ABPN
person